Form 4: Ocugen CEO Granted Over 3M Performance Stock Units & Options

Ocugen, Inc. CEO Shankar Musunuri received a significant grant of performance stock units and stock options, aligning executive incentives with future company performance.

Summary

• Shankar Musunuri, CEO and Director of Ocugen, Inc. (OCGN), was granted 3,123,201 Performance Stock Units (PSUs) on January 2, 2026.
• Each PSU represents a contingent right to receive one share of the Issuer's common stock upon the achievement of certain performance goals, subject to continued service.
• Musunuri also received an option to buy 3,123,201 shares of common stock at an exercise price of $1.38, granted on January 2, 2026.
• The option vests annually in equal installments over three years, commencing on January 2, 2027, subject to continued service.
• Following these transactions, Musunuri directly beneficially owns 4,955,924 shares of common stock and indirectly owns 1,145,299 shares through KVM Holdings, LLC.

Sentiment

Score: 7

Explanation: The grant of performance-based equity to the CEO is generally a positive signal as it aligns management's interests with long-term shareholder value creation and indicates confidence in future company performance. However, it is a standard compensation event rather than a direct operational or financial achievement.

Positives

• The grant of performance stock units and options aligns the CEO's incentives with long-term shareholder value creation.
• The significant number of units and options indicates confidence in future company performance and growth potential.
• The multi-year vesting schedule for options encourages continued service and sustained performance from the CEO.

Risks

• Achievement of performance goals for PSUs is contingent and not guaranteed, meaning the actual number of shares received could be less than the granted amount.
• The value of the options is dependent on the future stock price exceeding the exercise price of $1.38.

Future Outlook

The grants of performance-based equity suggest an expectation of future growth and achievement of specific performance milestones by Ocugen, Inc. The long-term vesting and option expiration dates indicate a multi-year strategic horizon for the company.

Management Comments

• Reflects a grant of performance stock units ('PSUs'). Each PSU represents a contingent right to receive one share of the Issuer's common stock upon the achievement of certain performance goals, subject to continued service with the Issuer on the applicable vesting dates.
• The option vests annually in equal installments over three years commencing on January 2, 2027, subject to continued service with the Issuer on the applicable vesting dates.

Industry Context

Executive equity grants, particularly those tied to performance, are a common practice in the biotechnology and pharmaceutical industries to incentivize leadership and align their interests with long-term shareholder value. This filing reflects standard corporate governance practices for executive compensation.

Comparison to Industry Standards

• The use of performance stock units (PSUs) and stock options is a standard compensation practice across the biotech industry, similar to companies like Moderna or BioNTech, which often use equity to attract and retain top talent and incentivize innovation.
• The multi-year vesting schedule for options (3 years) is typical for executive compensation plans, aiming to ensure long-term commitment, comparable to practices at companies such as Pfizer or Johnson & Johnson for their senior executives.
• The significant size of the grant for a CEO is common in growth-oriented biotech firms, where potential future value creation is high, aligning with compensation structures seen in companies developing novel therapies.

Related Party Transactions

• The reporting person is a member and officer of KVM Holdings, LLC and has voting and investment power over the 1,145,299 shares held by KVM Holdings, LLC, indicating an indirect beneficial ownership.

Stakeholder Impact

• Shareholders: Potential positive impact due to increased alignment of CEO's interests with long-term shareholder value.
• Employees: No direct impact mentioned, but a strong leadership incentive could indirectly benefit overall company performance and stability.

Next Steps

• Achievement of performance goals for PSUs.
• Vesting of stock options commencing January 2, 2027.

Key Dates

Keywords

Ocugen, OCGN, Shankar Musunuri, CEO, Director, Performance Stock Units, PSUs, Stock Options, Insider Trading, Executive Compensation, Equity Grant, SEC Form 4